Evidence map›Paper›PMID 36510308›Full record

ArticleBMC research notes2022

Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis.

Nora Hutchinson, Katarzyna Klas, Benjamin G Carlisle, Maciej Polak, Jonathan Kimmelman, Marcin Waligora

Abstract read
In one paragraph

Article in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nora HutchinsonStudies of Translation, Ethics, and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, QC, Canada.
Katarzyna KlasResearch Ethics in Medicine Study Group (REMEDY), Faculty of Health Sciences, Jagiellonian University Medical College, Michalowskiego 12, PL-31-126, Krakow, Poland.
Benjamin G CarlisleBerlin Institute of Health at Charité (BIH), BIH QUEST Center for Transforming Biomedical Research, Berlin, Germany.
Maciej PolakResearch Ethics in Medicine Study Group (REMEDY), Faculty of Health Sciences, Jagiellonian University Medical College, Michalowskiego 12, PL-31-126, Krakow, Poland.
Jonathan KimmelmanStudies of Translation, Ethics, and Medicine (STREAM), Biomedical Ethics Unit, McGill University, Montreal, QC, Canada.
Marcin WaligoraResearch Ethics in Medicine Study Group (REMEDY), Faculty of Health Sciences, Jagiellonian University Medical College, Michalowskiego 12, PL-31-126, Krakow, Poland. m.waligora@uj.edu.pl.ORCID http://orcid.org/0000-0002-1553-1416

Funding

Narodowe Centrum Nauki 2020/01/0/HS1/00024
6 · The paper itself

Abstract

objectiveCompetition among trials for patient enrollment can impede recruitment. We hypothesized that this occurred early in the COVID-19 pandemic, when an unprecedented number of clinical trials were launched. We performed a simple and multivariable regression analysis evaluating the relationship between the proportion of SARS-CoV-2 investigational trial sites within each USA state with unsuccessful patient-participant recruitment and: (i) the proportion of cases required to reach state recruitment goals; (ii) state population based on data from the US Census; and, (iii) number of trial sites per state.

resultsOur study included 151 clinical trials. The proportion of trials with successful recruitment was 72.19% (109 of 151 trials). We did not find a significant relationship between unsuccessful patient-participant recruitment, state recruitment goals, state population or the number of trial sites per state in both our simple and multivariable regression analyses. Our results do not suggest that early in the COVID-19 pandemic, competition for patient-participants impeded successful recruitment in SARS-CoV-2 trials. This may reflect the unique circumstances of the first few months of the pandemic in the United States, in which the number and location of SARS-CoV-2 cases was sufficient to meet trial recruitment requirements, despite the large number of trials launched.

Indexed as

COVID-19SARS-CoV-2Cohort StudiesHumansPandemicsPatient SelectionUnited StatesClinical trialsCompetitionCOVID-19Patient-participant recruitmentSARS-CoV-2United States

Identifiers

PMID36510308
PMCPMC9742655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.